Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

SSAB at COP28: Ambition and speed must increase

SSAB representatives will participate in more than 20 seminars and round tables during the United Nations Climate Change Conference, COP28, in Dubai. Our key message is that we have the technology to get rid of fossil emissions from steelmaking – now we need policymakers to create the enabling framework for a faster roll-out. Photo: SSAB CTO Martin Pei and fossil-free steel bar. This is the third year that SSAB is joining the annual climate change conference as part of Business Sweden’s delegation. As leader of the green transition in the steel industry, SSAB is committed to

Metsä Group’s Kuura[®] textile fibre gained important recognition in sustainability matters

Kuura textile fibre, which is made from Metsä Group’s softwood pulp, received a ‘Green Shirt’ rating based on the evaluation arranged by not-for-profit environmental organisation Canopy. Their annual Hot Button Ranking is a well-established tool used in the global textile and fashion industries to assess the sustainability of wood-based textile fibres.Espoo, Finland (30th November 2023) Metsä Group’s Kuura textile fibre has achieved high scores based on the Hot Button Ranking  evaluation arranged by the Canadian not-for-profit environmental organisation

Lundbeck R&D Event to showcase innovative pipeline

H. Lundbeck A/S (Lundbeck) is hosting an R&D Event in London today, providing analysts and investors with an update on the progress of its R&D transformation.Today, Lundbeck is hosting an investor R&D Event in London, offering insights into the company’s commitment to leveraging its transformed R&D pipeline for future growth.   The event will feature Lundbeck's CEO Charl van Zyl, Head of R&D Johan Luthman, and other R&D leaders. Lundbeck experienced significant R&D milestones in 2023, securing two FDA approvals, eight key headline results, a phase II proof of concept with a novel

Prostatype Genomics AB (publ) changes Certified Adviser to Carnegie Investment Bank AB (publ)

Prostatype Genomics AB today announces a change of Certified Adviser from Erik Penser Bank AB to Carnegie Investment Bank AB (publ).Prostatype Genomics has entered into an agreement with Carnegie Investment Bank AB (publ) regarding the position as Certified Adviser. Carnegie Investment Bank AB (publ) will take over as Certified Adviser on November 30, 2023. Until then, Erik Penser Bank AB will continue to act as Certified Adviser to the company.

Misen Energy AB (publ) changes liquidity provider and Certified Adviser to Carnegie Investment Bank AB (publ)

Misen Energy AB (publ) announces today that it is changing liquidity provider and Certified Adviser from Erik Penser Bank AB to Carnegie Investment Bank AB (publ). Misen Energy AB (publ) has terminated the assignment regarding liquidity guarantee with Erik Penser Bank AB and has appointed Carnegie Investment Bank AB (publ) as the new liquidity provider for the company's shares that are listed on the Nasdaq First North Growth Market in Stockholm. The change of liquidity provider is in accordance with Nasdaq Stockholm's regulations regarding liquidity providers. In its role as liquidity

Biosergen AB changes Certified Adviser to Carnegie Investment Bank AB (publ)

Biosergen AB today announces a change of Certified Adviser from Erik Penser Bank AB to Carnegie Investment Bank AB (publ).Biosergen AB has entered into an agreement with Carnegie Investment Bank AB (publ) regarding the position as Certified Adviser. Carnegie Investment Bank AB (publ) will take over as Certified Adviser on November 30, 2023. Until then, Erik Penser Bank AB will continue to act as Certified Adviser to the company.

Interim Report January–September 2023

ChromoGenics increases order intake and continues to lower costsQ3 2023 (July–September) · Net sales amounted to SEK 1.6 (3.5) million, a decrease of SEK 1.9 million compared to the corresponding quarter in 2022. · Operating costs excluding depreciation and amortization and financial expenses amount to SEK 12.2 (22.0) million in Q3 2023 and correspond to a decrease in costs of SEK 9.7 million or 44 percent. · Earnings before tax, depreciation/amortization and financial items (EBITDA) improved in the quarter by SEK 2.5 million and amount to SEK -9.2 (-11.7) million. · Cash flow

Beijer Ref presents new financial targets

Beijer Ref’s board has decided on new financial targets. The new targets are based on continued good opportunities for growth as well as increased clarity towards the market and investors. Christopher Norbye, CEO Beijer Ref, comments: "We see that the market has developed positively and the company is in a good position. The existing platform is strong and we continue to build for further growth.” New financial targets for the next 5 years: New target: Sales growth of 10-15% annually Old target: Grow at a higher rate than the market New target: EBITA margin of 10-12%

Positive tax restructuring in Beijer Ref's US operations

During the year, a tax restructuring took place in the Beijer Ref US operations, which has resulted in an increase in the tax base of the US operations by an additional approximately MUSD 235. Together with the now expanded tax base, the payable tax in the US operations is expected to be positively impacted by approximately MUSD 200 over a 15-year period.The lower payable tax will be recognized on an ongoing basis as deferred tax liability, which is why profit in the coming years will not be affected. The tax restructuring also means that a currently recognized deferred tax liability of

Calliditas initiates clinical study to evaluate setanaxib in Alport Syndrome

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced the initiation of a Phase 2 clinical study to evaluate setanaxib in Alport syndrome.Calliditas is a company focused on developing and commercializing novel treatments in rare diseases with significant unmet medical needs. This randomized, double-blind, placebo-controlled study will evaluate setanaxib in approximately 20 patients with a genetic diagnosis of Alport syndrome and significant proteinuria despite treatment with a renin-angiotensin system (RAS) blocker. The duration of treatment is

Wärtsilä contracted to supply two 30 MW power plants for Indonesian state-owned utility

Wärtsilä Corporation, Press release, 30 November at 9:30 AM EETTechnology group Wärtsilä will supply the generating sets for two Indonesian power plants. The order has been placed by KEPCO E&C, a member of the consortium of KEPCO E&C-Adhi Karya, the consortium to build the plants for the Indonesian state-owned utility PLN. The order has been booked by Wärtsilä in November 2023. The Sumbawa-2 plant located on Sumbawa island and the Tobelo plant on North Maluku will each operate with three Wärtsilä 31DF dual-fuel engines delivering an output of 30 MW. Initially they will be fuelled by mix

Redwood Pharma AB (publ) changes Certified Adviser to Carnegie Investment Bank AB (publ)

Redwood Pharma AB (publ) today announces a change of Certified Adviser from Erik Penser Bank AB to Carnegie Investment Bank AB (publ).Redwood Pharma has entered into an agreement with Carnegie Investment Bank AB (publ) regarding the position as Certified Adviser. Carnegie Investment Bank AB (publ) will take over as Certified Adviser on November 30, 2023. Until then, Erik Penser Bank AB will continue to act as Certified Adviser to the company.

Wyld Networks’ Interim Report Q3 2023

WYLD COMMENCES SHIPMENT OF PRODUCT IN OCTOBER 2023 Financial Summary, Q3 2023 +-----------------------------------------+-------+------+-------+-----------+|  |Q3 (Jul-Sept) |9 months (Jan-Sept)|+-----------------------------------------+-------+------+-------+-----------+|2023 |2022 |2023 |2022 |+-----------------------------------------+-------+------+-------+-----------+|Total income KSEK |2,582 |933 |5,246 |2,917 |+-----------------------------------------+---

KGC regions extends agreement regarding support and maintenance of the electronic health record system Cambio COSMIC

The agreement between the regions within Client group Cosmic (KGC) and Cambio Healthcare Systems AB (Cambio) regarding support and maintenance of the electronic health record system Cambio COSMIC (Cosmic) is extended, starting on 1 January 2024. The agreement runs for five years, with the possibility of extension for a further three years.KGC consists of eight regions and the privately owned Capio St. Göran's hospital, each of which has individually chosen Cosmic as its electronic health record system. KGC was formed in 2007 to give the regions and Capio S:t Göran the conditions to, in

Crunchfish publishes interim report Q3 2023

Today, Crunchfish AB (“Crunchfish”) publishes the company’s interim report for the third quarter and nine months of 2023. Below is a brief summary of the report.Group financials 2023-07-01 2022-07-01 2023-01-01 2022-01-01 2023-09-30 2022-09-30 2023-09-30 2022-09-30         Net sales (SEK) 189 180 5 805 573 654 483 6 156 359Profit or loss -7 021 991 -900 384 -22 489 595 -14 381 760before tax (SEK)Earnings per -0,21 -0,03 -0,68 -0,46share (SEK)Equity-assets

CLS Selects Quest International to Provide Aftermarket Service and Logistics Operations to boost commercial expansion

Lund, Sweden – Clinical Laserthermia Systems AB (publ) (CLS) Clinical Laserthermia Systems AB (publ) (“CLS” or “the Company”) announces today that its US subsidiary has selected Quest International, a global aftermarket technical service provider to OEMs, to provide service and logistics operations for the US market. Under the agreement, Quest will provide end to end white glove service management including field services, depot repair, and warehousing and logistics support for CLS’s soft tissue ablation system, the TRANBERG Thermal Therapy System.The collaboration is an important part of

Rightbridge Ventures Group Announces Exclusive Gaming Partnership with Crazy Frog and CF Entertainment

Rightbridge Ventures Group AB (publ) (“Rightbridge”or “Rightbridge Ventures”) and CF Entertainment AB (“CF Entertainment”) have today signed an exclusive collaboration agreement for the development of mobile, web, and console games involving their globally recognized IP, Crazy Frog. The agreement initially spans two years and will automatically be extended for one year at a time, provided that revenues of 2 MSEK are generated for CF Entertainment during the contract period. Initially, but no later than February 28, 2024, Rightbridge Ventures is to pay a deductible advance of 1 MSEK to CF

Change of number of shares and votes in Truecaller AB (publ)

The number of shares and votes in Truecaller AB (publ) (“Truecaller”) has changed during November 2023 as a result of exercise of employee stock options of series 2021:6 in accordance with Truecaller's incentive programs.Through the exercise of the employee stock options, the number of shares has increased by 25 and the share capital has increased by SEK 0.05. As of 30 November 2023, the last trading day of November, the number of shares in Truecaller amounts to 381,187,529, of which 46,783,800 are ordinary shares of series A with 10 votes per share, 328,803,729 are ordinary shares of

Arctic Paper changes its liquidity provider to Carnegie

Arctic Paper S.A. has terminated the liquidity provider assignment with Erik Penser and has appointed Carnegie Investment Bank AB as new liquidity provider for the company's shares on Nasdaq Stockholm. The arrangement is in accordance with the framework of Nasdaq Stockholm's rules on liquidity providers.In the role of liquidity provider Carnegie undertakes to continuously quote prices for the Arctic Papers share in accordance with the from time-to-time applicable minimum requirements for liquidity providers set out by Nasdaq Stockholm. The purpose is to improve the liquidity of the share

BioStock: Great interest in Dicot’s LIB-01

Many interested parties are keeping an eye on the development of LIB-01, Dicot's drug candidate for the treatment of erectile dysfunction, and the interest only seem to increase. At least if you ask the company's CEO, Elin Trampe, who BioStock talked to in connection with the Sexual Medicine Society of North America's annual conference.Read the full article at biostock.se : https://www.biostock.se/en/2023/11/great-interest-in-dicots-lib-01/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Elicera Therapeutics changes Certified Adviser and Liquidity provider to Carnegie Investment Bank AB (publ)

Elicera Therapeutics has entered into agreements with Carnegie Investment Bank AB (publ) regarding the position as Certified Adviser and Liquidity provider. Carnegie Investment Bank AB (publ) will take over as Certified Adviser and Liquidity provider on November 30, 2023. Until then, Erik Penser Bank AB will continue to act as Certified Adviser and Liquidity provider to the company.     The information was submitted for publication distributed through the contact person below at 08;12 CET on November 30, 2023.     For further information please contact: Jamal El-Mosleh,

There are no items matching the current filter
There are no more items matching the current filter
Back to top